Efficiency of Menopausal Hormone Therapy in Women with Menopausal Syndrome

Bibliography link: Vinokurova E.A., Gorodnicheva I.E., Kiseleva M.A. Efficiency of Menopausal Hormone Therapy in Women with Menopausal Syndrome. Doctor.Ru. 2020; 19(1): 38–41. (in Russian) DOI: 10.31550/1727-2378-2020-19-1-38-41
4 February 12:36

Study Objective: to assess the rate of extragenital pathologies in patients with moderate to severe menopausal syndrome (MPS), and the efficiency of menopausal hormone therapy (MHT) with a drug containing 17β-estradiol (estradiol hemihydrate) and didrogesteron.

Study Design: observational clinical study.

Materials and Methods. 166 women with moderate to severe MPS were examined. All patients were prescribed an MHT drug containing an estrogen component (17β-estradiol — estradiol hemihydrate 2.06mg, equivalent to estradiol — 2.0mg) and gestagen component (didrogesteron 10mg), 1 tablet once daily for 6 months. MPS severity was assessed using the menopausal index proposed in 1959 by H. Kupperman et al., as modified by E. V. Uvarova. If the total value of symptoms was 35–58 points, moderate MPS was diagnosed (n = 70; 42.2%); if the value was over 58 points, it was a case of severe MPS (n = 96; 57.8%). Patients’ status dynamics and MPS severity were assessed prior to MHT, and then 1, 3 and 6 months after treatment initiation.

Study Results. It was found out that, among extragenital pathologies in patients with MPS, most frequently registered were chronic upper respiratory tract inflammations (82.0%), endocrine pathologies (61.4%), stage II and III obesity (44.6%). In moderate MPS, one month of therapy resulted in statistically significant reduction in the amended menopausal index (AMI) of approx. 18 points (37.5%), in 3 months, the reduction was by 22 points (45.8%) (p < 0.05), in 6 months — by 34 points (70.8%) (p < 0.05). In severe MPS, one month of therapy resulted in statistically significant reduction in the AMI of approx. 13 points (21.0%) (p > 0.05), in 3 months, the reduction was by 24 points (38.7%) (p < 0.05), in 6 months — by 38 points (61.3%) (p < 0.05). In one month of MHT, all patients did not have any complaints of flushes.

Conclusion. The rate of extragenital pathologies in women with MPS was high. Once somatic diseases were eliminated, patients demonstrated high therapeutic efficiency of the two-phase drug containing estradiol hemihydrate and didrogesteron in relief of neurovegetative and psychoemotional disorders in menopausal syndrome.

Contribution: Vinokurova, E.A. — study design, review of critically important material, approval of the manuscript for publication, patient examination and treatment, thematic publications reviewing; Gorodnicheva, I.E. — collection of clinical materials, data analysis and interpretation; Kiseleva, M.A. — thematic publications reviewing, statistical data processing, manuscript preparation.

Conflict of interest: The authors declare that they do not have any conflict of interests.

Received: 27.12.2019
Accepted: 21.01.2020

E.A. Vinokurova (Corresponding author) — Tyumen State Medical University of the Ministry of Health of the Russian Federation; 54 Odesskaya Str., Tyumen, Russian Federation 625023. E-mail:

I.E. Gorodnicheva — Tyumen State Medical University of the Ministry of Health of the Russian Federation; 54 Odesskaya Str., Tyumen, Russian Federation 625023. E-mail:

M.A. Kiseleva — Tyumen State Medical University of the Ministry of Health of the Russian Federation; 54 Odesskaya Str., Tyumen, Russian Federation 625023. E-mail:



Efficiency of menopausal syndrome (MPS) therapy with a two-phase drug containing 17β-estradiol and didrogesteron, points of amended menopausal index (AMI)


* Statistically significant differences parameters vs. prior to therapy (p < 0.05).

4 February 12:36
  1. Gass M.L.S., Maki P., Shifren J.L., Schnatz P.F., Kaunitz A.M., Shapiro M. et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685–6. DOI: 10.1097/GME.0000000000000491
  2. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109–50. DOI: 10.3109/13697137.2015.1129166
  3. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015; 175(4): 531–9. DOI: 10.1001/jamainternmed.2014.8063
  4. Oboskalova T.A., Koval M.V. Influence of menopausal hormone therapy on uterine myoma in menopausal women. Ural Med. J. 2017; 6(150): 5–9. (in Russian)
  5. Kuznetsova I.V. Menopausal symptoms and sleep disorders in women: possibilities of alternative therapy. Obstetrics and Gynecology: News, Opinions, Training. 2019; 7(1): 85–91. (in Russian). DOI: 10.24411/2303-9698-2019-11012
  6. Andreeva E.N., Simonovskaya Kh.Yu., Trush M.V. I hear voice from distant future very often... Anti-ageing strategies in obstetrics/gynecology. StatusPraesens. Obstetrics, Gynecology, Sterile Marriage. 2016;3(32): 80–6. (in Russian)
  7. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155–74; quiz 1173-4. DOI: 10.1097/GME.0000000000000546
  8. Gurina A.V. Study of comorbid pathologies in patients with uterine fibroid. Eurasian Scientific Union. 2019; 8-2(54): 119–20. (in Russian)
  9. Chukayeva I.I., Samorodskaya I.V., Larina V.N. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Therapeutic archive. 2018; 8: 125–30. (in Russian). DOI: 10.26442/terarkh2018908125-130
  10. Barnett K., Mercer S., Norbury M., Watt G., Wyke S., Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836): 37–43. DOI: S0140-6736(12) 60240-2
  11. Wallace E., Guthrie B., Lewi C., Fahey T., Smith S. Managing patients with multimorbidity in primary care. BMJ. 2015; 350: h176. DOI: 10.1136/bmj.h176
  12. Sukhikh G.T., Smetnik V.P., Andreeva E.N., Balan V.E., Gavisova A.A., Grigoryan O.R. et al. Menopausal hormone therapy and female health in mature age. Problems of reproduction. 2018; 24(S6): 727–56. (in Russian)
  13. Balan V.E., Tikhomirova Е.V. Menopausal hormone therapy: maximum benefit with minimal risks. Medical alphabet. 2018; 1-6(343): 6–9. (in Russian)
  14. Vorontsova A.V., Zvychainyi M.A., Oboskalova T.A., Prokhorova O.V. Stage of “consultation” of women of perimenopausal age — necessary condition for optimization of tactics of administration. Ural Med. J. 2017; 6(150): 10–17. (in Russian)
  15. Stevenson J.C., Durand G., Kahler E., Pertyński T. Oral ultra-low dose continuous combined hormone replacement therapy with 0,5 mg 17β-oestradiol and 2,5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas. 2010; 67(3): 227–32. DOI: 10.1016/j.maturitas.2010.07.002
  16. Zaydieva Y.Z. Menopausal hormone therapy and cancer risks of reproductive system. Literature review. Medical alphabet. 2019; 1(1): 42–50. (in Russian). DOI: 10.33667/2078-5631-2019-1-1(376)-42-50
  17. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hub­bard V.S. et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology American/Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 suppl.2): S76–99. DOI: 10.1161/01.cir.0000437740.48606.d1
  18. Gurka M.J., Vishnu A., Santen R.J., DeBoer M.D. Progression of metabolic syndrome severity during the menopausal transition. J. Am. Heart Assoc. 2016; 5(8): pii: e003609. DOI: 10.1161/JAHA.116.003609
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)